Thirty-eight percent of hospital inpatients require insulin — the second highest-alert medication in the building*. Most health systems still manage it through manual protocols and sliding-scale math at the bedside. The clinical and financial consequences are documented, measurable, and increasingly tied to federal regulatory exposure.
This post draws on case study data featured in The Drip podcast, produced by Glytec, to examine what changes when a health system moves from high-risk manual glycemic workflows to intelligent glycemic management. The evidence spans clinical outcomes, nursing workflow, length of stay, and CMS eCQM readiness — and it is specific.
Manual insulin protocols create significant clinical variation that contributes to avoidable hypoglycemic events.
AdventHealth documented a 75% reduction in first-time provider calls per patient day after implementing GlytecOne.
Grady Health Systemc documented a 98% reduction in severe hypoglycemia (<70 mg/dL) using Glucommander. Individual results may vary.
GlytecOne customers have documented length-of-stay reductions averaging 3.18 days across deployed sites.
Severe hypoglycemia and severe hyperglycemia are now CMS hospital harm eCQMs; non-reporting hospitals risk forfeiting 25% of the annual Medicare payment update.
Why Manual Glycemic Protocols Create Avoidable Clinical Risk
Managing insulin manually requires a nurse to cross-reference prior blood glucose readings, account for meal delivery timing, consider kidney function, and calculate a sliding-scale dose — often at high-acuity moments during a shift. Protocol compliance with manual workflows averages below 60%.
That gap between what the protocol requires and what consistently happens at the bedside generates clinical variation. Clinical variation in high-alert medication management is not a staffing problem. It is a structural systems failure.
When variation is the norm, patients spend more time outside of target glycemic range. That extends length of stay, increases the likelihood of secondary complications, and adds cost that compounds across the patient population.
What Intelligent Glycemic Management Changes at the Bedside
Glucommander, the FDA-cleared insulin dosing solution at the heart of GlytecOne, provides dosing recommendations for clinician review and confirmation. The algorithm analyzes the patient’s current glucose level, the velocity of glucose change, and the active insulin curve, then surfaces a recommendation the nurse reviews and acts on.
The cognitive burden of manual calculation shifts from the bedside clinician to the platform. AdventHealth documented that this change reduced first-time provider calls by 75% per patient day. Nursing staff at AdventHealth also reported up to 72 minutes of time saved per IV insulin patient per shift.
That reclaimed time does not disappear. It goes back to direct patient care, monitoring, and throughput — functions that are difficult to expand without structural changes to the workflow.
Documented Intelligent Glycemic Management Outcomes Across Health Systems
Grady Health System saw a 98% reduction in severe hypoglycemia using Glucommander. Sentara Healthcare documented a 57% reduction across 12 hospitals, with zero post-operative blood glucose readings above 200 in cardiac surgery within months of implementation.
AdventHealth’s head-to-head cardiovascular surgery study comparing Glucommander to EndoTool documented 62.6% fewer preventable hypoglycemia adverse drug events with Glucommander. These are not modeled projections. They are documented outcomes at named institutions.
GlytecOne has seen documented length-of-stay reductions averaging 3.18 days. Riverside Healthcare documented $2.6 million in annualized avoided costs at a 467% return on investment1. Individual results may vary.
CMS eCQM Accountability and the Financial Urgency for Health Systems
Severe hypoglycemia and severe hyperglycemia are now CMS hospital harm eCQMs — electronic clinical quality measures. These are not internal quality committee metrics. They are reportable to Medicare and tied to payment.
Hospitals that do not report on these measures risk forfeiting 25% of their annual Medicare payment update. That penalty compounds annually. In late 2027, CMS expands public reporting of glycemic performance metrics, making these results visible to the public and to hospital boards.
Health systems that continue managing insulin with manual protocols or unvalidated calculators are operating below a documented standard of care while carrying increasing regulatory and financial exposure.
Standardization as an Enterprise Strategy
Intelligent glycemic management is not a unit-level nursing initiative. It is an enterprise-wide discipline. The health systems that have documented the strongest clinical and financial outcomes built structured adoption programs — dedicated super users, embedded EHR integration, and consistent staff education.
Glucommander integrates directly with Epic, Cerner, and Meditech. It does not require a separate log-in or a disconnected workflow. The dosing recommendation surfaces within the existing clinical environment, reducing friction and supporting adoption.
The regulatory reporting required for CMS eCQM compliance can become a structural byproduct of providing standardized care — rather than a separate manual documentation burden.
* NIH
1. As stated by LaTivia Carr, CNO Riverside Healthcare
For further reading and reference citations, please review our case studies on the Glytec Website.
Review how your program can strengthen glycemic measure readiness and accountability.
For full case studies and clinical evidence, visit glytec.com/information-hub/.
What is intelligent glycemic management in hospitals?
Intelligent glycemic management uses FDA-cleared clinical decision support software to provide evidence-based insulin dosing recommendations for clinician review. It replaces manual sliding-scale calculations with standardized, algorithm-supported dosing, helping reduce clinical variation and improve patient safety at the bedside.
How does Glucommander help reduce hypoglycemia in inpatients?
Glucommander provides dosing recommendations based on the patient’s current glucose level, rate of change, and active insulin curve. By supporting consistent, evidence-based insulin management, it helps clinical teams keep patients in target glycemic range and reduce the frequency of severe hypoglycemic events.
What are CMS glycemic eCQMs and why do they matter?
CMS hospital harm eCQMs for glycemic management measure severe hypoglycemia and severe hyperglycemia as reportable quality indicators. Hospitals that fail to report risk forfeiting 25% of their annual Medicare payment update. Public reporting expands in late 2027, making glycemic performance visible to boards and the public.
How much nursing time can glycemic management software save?
Across GlytecOne-deployed sites, nurses have documented up to 72 minutes of time saved per IV insulin patient per shift. AdventHealth documented a 75% reduction in first-time provider calls per patient day. Individual results may vary based on patient population and workflow context.
What is the difference between FDA-cleared and FDA-approved for medical software?
FDA-cleared means a device has been reviewed through the 510(k) pathway and found substantially equivalent to a predicate device. FDA-approved is a separate, more stringent process for higher-risk devices. Glucommander is FDA-cleared as a Class II Software as a Medical Device, not FDA-approved.
What is an electronic glycemic management system (eGMS)?
An electronic glycemic management system (eGMS) is a software tool designed to support insulin dosing decisions for hospitalized patients. An FDA-cleared eGMS, such as Glucommander, is classified as a Class II Software as a Medical Device and uses a computer-guided algorithm to calculate recommended insulin doses based on patient glucose values. Clinicians review and confirm all recommendations before action is taken. An eGMS is an adjunct to clinical judgment, not a substitute for it.
Can a hospital use its EHR instead of a dedicated glycemic management platform?
EHR-native insulin calculators are not FDA-cleared and lack the clinical evidence base of dedicated glycemic management software. Glucommander has 20 years of continuous FDA clearance. Unvalidated EHR-based calculators carry regulatory and liability exposure that dedicated platforms do not.
What ROI have hospitals documented from Glucommander deployment?
Riverside Healthcare documented $2.6 million in annualized avoided costs at 467% ROI. The Midwestern health system documented $40 million in avoided costs within 12 months of implementation. Individual results vary based on patient volume, baseline glycemic performance, and care setting.
- Manual insulin protocols generate clinical variation that is a structural systems failure, not a staffing problem.
- AdventHealth documented a 75% reduction in first-time provider calls per patient day after implementing FDA-cleared glycemic management.
- Grady Health System documented a 98% reduction in severe hypoglycemia using Glucommander
- Sentara documented a 57% reduction across 12 hospitals. Individual results may vary.
- CMS hospital harm eCQMs for glycemic management carry a 25% annual Medicare payment update forfeiture for non-reporting hospitals.
- Intelligent glycemic management supports CMS eCQM compliance as a byproduct of standardized care delivery.
- GlytecOne customers have documented length-of-stay reductions averaging 3.18 days and annualized cost avoidance at multiple named institutions. Individual results may vary.
Glucommander is an FDA-cleared Class II medical device. Rx only. Individual results may vary. This content is based on The Drip podcast by Glytec. For full case studies and resources, visit glytec.com/information-hub/
